Investor Presentaiton
MAT2Ai Combination Strategy
AMGEN®
Clinical Combination focus on IDE397 + PRMT5MTA based on Compelling Preclinical Efficacy
IDE397 + MTA-Cooperative PRMT5 Inhibitor
enables Maximal Pathway Suppression*
Maximal Pathway
Suppression
Methionine
Hit 2
MAT2A
IDE397
Deep and Durable Anti-Tumor and PD Response with Combination*
PRMT5MTA-1
NSCLC MTAP (-/-) CDX
-O- Vehicle
IDE397 3 mg/kg
IDE397 30 mg/kg
2000-
PRMT5MTA-125 mg/kg
PRMT5MTA-1 100 mg/kg
IDE397 3 mg/kg +
PRMT5MTA-1 25 mg/kg
PRMT5MTA-1
Pancreatic MTAP (-/-) CDX
PRMT5MTA-1 25 mg/kg
-- Vehicle
▲ IDE397 3 mg/kg
IDE397 3 mg/kg +
PRMT5MTA-1 25 mg/kg
1500-
MTA
Hit 1
MTA
PRMT5
MTAP
MTA
Hit 3
PRMT5MTA
MTA
SAM
Methylation of
Splicing Factors
(SDMA)
In Vivo Efficacy Confirmed in Multiple Models
Pre-mRNA Splicing
(Essential)
Enhanced Combination Efficacy Observed in multiple Tumor
Indications and Across Representative PRMT5MTA Inhibitors
+
Mean Tumor Volume (mm³) ± S.E.M.
1500-
1000-
500-
0+
ō
0
10
20
30
40
50
60
Study Day
Mean Tumor Volume (mm³) ± S.E.M.
1000-
500-
0-
10
20
30
40
50
60
Study Day
MTAP-deleted Tumor SDMA IHC Scores
PRMT5MTA-2
NSCLC MTAP (-/-) CDX
-- Vehicle
100%
PRMT5MTA-2 30 mg/kg
IDE397 3 mg/kg +
75%-
✰IDE397 3 mg/kg
PRMT5MTA-2 30 mg/kg
2000-
50%-
1500-
25%-
Mean Tumor Volume (mm³) ± S.E.M.
1000-
500-
IDE397
Vehicle
3 mg/kg
☐ ☐ ☐ ☐
3+
2+
1+
0
25
* Clinical evaluation pursuant to Amgen Clinical Trial Collaboration and Supply Agreement for clinical
evaluation of IDE397 and AMG 193, an Amgen investigational MTA-cooperative PRMT5 inhibitor;
Amgen will sponsor the study; IDEAYA and Amgen will jointly share external costs of the study
T
0
10
20
30 40 50 60
Study Day
SDMA IHC nuclear staining intensity distribution, pathologist scored, as
percent of total tumor cells evaluated per sample; tumor samples from
HCT116 MTAP (-/-) CDX models collected 2 hrs post-dose on Treatment Day 2
+ IDEAYA Data: AACR 2023, M. Fischer et al. based on evaluation of multiple representative MTA-cooperative PRMT5 inhibitors,
designated as PRMT5MTA-1, PRMT5MTA-2
IDEA A
BIOSCIENCES
PRMT5¡MTA
IDE397 +
PRMT5iMTAView entire presentation